At-a-Glance:
| Company |
Cell Biologics |
|---|
| Specialties |
Primary cells, cell culture media, engineered cells, custom isolation services |
|---|
| Mission |
To provide high-quality human and animal primary cells and customized solutions to researchers worldwide, while developing therapeutic platforms targeting inflammatory diseases and novel drug delivery systems. |
|---|
| Noteworthy |
Cell Biologics was the first company to develop a proprietary technology to culture mouse primary endothelial cells. |
|---|
| Location |
Chicago |
|---|
Cell Biologics is a Chicago-based manufacturer of primary cultured cells and cell culture products, supplying researchers across academia and industry. The company is perhaps best known for a distinction it holds in the field: it was the first to develop a proprietary technology for culturing mouse primary endothelial cells—a product line that has since become an important resource for in vitro research in areas including vascular biology, blood-brain barrier research, tumor angiogenesis, and drug targeting.
That early focus on endothelial cells established a foundation that the company has built on. Today, Cell Biologics offers a broad catalog of human and animal primary cells, including endothelial, epithelial, tumor, and stem cells. The full product range extends to optimized cell culture media, supplements, reagents, and assay kits.
A defining aspect of Cell Biologics' offering is its custom cell isolation service. Researchers with specific scientific needs can request primary cells isolated to their specifications—a capability that addresses the reality that off-the-shelf options do not always align with the demands of specialized experimental designs. The company also offers an immortalization service using SV40 and hTERT approaches.
In recent years, Cell Biologics has expanded its portfolio into immune cells and engineered cell services, areas the company identifies as current priorities. Knockout and knockdown engineered cell lines are among the additions being incorporated into the catalog, reflecting growing demand from researchers. The company also offers advanced technology services including AAV production, an endothelial-specific adenoviral overexpression system, and library generation services covering RNA-seq, METHYL-seq, and ChIP-seq workflows.
Looking ahead, Cell Biologics is extending its work beyond cell supply into therapeutic development. The company is actively developing therapeutic platforms targeting inflammatory diseases, as well as novel delivery systems for therapeutic biologics.
For scientists working with primary cells, the combination of catalog depth, custom services, and expanding immune and engineered cell offerings makes Cell Biologics a valuable resource for a range of experimental needs—from basic research through preclinical studies.